Reduced Efficacy

Drug concentration at desired location is limited by low percentage that reaches the target and/or potential side effects and complications in other parts of the eye that preclude higher doses.

Reduced Access

Invasive surgical approaches must be performed in an operating room which increases cost, reduces access, and delays treatment (with potentially irreversible consequences).

Patient Burden

Negative effects of poor outcomes and exposure to difficult surgical interventions with awkward recovery protocols and potential long-term consequences (i.e. cataract formation).

Dragonfleye has created a device to enable minimally invasive, targeted delivery to the suprachoroidal and subretinal spaces in an office setting.

• Novel device designed to perform a broad range of ophthalmic procedures outside the operating room
• High precision controls advance a micro needle and deliver the treatment fluid to the target location. The needle comes out of the inner face of the device, providing better and more direct access to the target area than a syringe, to allow for more precise posterior eye interventions in outpatient settings
• Less invasive methods minimize procedural complexity, which could reduce the risk of complications, recovery time and healthcare costs
• More direct access to the treatment area could result in better patient outcomes
• The device could be used to perform a broad range of ophthalmic procedures that require access to the posterior of the eye including suprachoroidal viscopexy^TM (SCVEXY^TM) for the treatment of retinal detachment